List of investigational sleep drugs
This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Insomnia
GABAA receptor potentiators
- EVT-201 – GABAA receptor positive allosteric modulator
- Lorediplon (GF-015535-00) – GABAA receptor positive allosteric modulator
- Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator
Orexin receptor antagonists
- Seltorexant (MIN-202, JNJ,42847922, JNJ-922) – selective OX2 receptor antagonist
- Vornorexant (ORN-0829, TS-142) – dual OX1 and OX2 receptor antagonist
Melatonin receptor agonists
- Piromelatine (Neu-P11) – melatonin receptor agonist and 5-HT1A and 5-HT1D receptor agonist
Nociceptin receptor agonists
- Sunobinop (IMB-115, IT-1315, S-117957, V-117957) – nociceptin receptor agonist
Hypersomnia/narcolepsy
Orexin receptor agonists
- Danavorexton (TAK-925) – OX2 receptor-selective agonist via IV infusion[1]
- TAK-994 – OX2 receptor agonist pill (orally available) [1]
Monoaminergics
- Flecainide/modafinil (THN-102) – modafinil (dopamine reuptake inhibitor) and flecainide (antiarrhythmic) combination
- Mazindol controlled release (NLS-1001, NLS-1) – norepinephrine-predominant serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)
- Reboxetine (AXS-12) – norepinephrine reuptake inhibitor (NRI)
GHB receptor agonists
- FT-218 (sodium oxybate controlled release) – GHB and GABAB receptor agonist
GABAA receptor inhibitors
- Pentylenetetrazole (BTD-001) – GABAA receptor negative allosteric modulator
See also
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.